Alnylam Announces Interim Phase 1 Data of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown of Ttr That Is Sustained at Six Months Following a Single Dose
Alnylam宣布Nucresiran (Aln-Ttrsc04)第1阶段中间数据显示,在单剂后6个月持续的Ttr迅速下降
Alnylam Announces Interim Phase 1 Data of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown of Ttr That Is Sustained at Six Months Following a Single Dose
Alnylam宣布Nucresiran (Aln-Ttrsc04)第1阶段中间数据显示,在单剂后6个月持续的Ttr迅速下降
使用浏览器的分享功能,分享给你的好友吧